Uchenna Emechebe

Scientific Project Manager - Model Informed Drug Development at Metrum Research Group

Uchenna Emechebe has a diverse work experience spanning multiple industries. Starting in 2015, they worked as a Technology Transfer and Business Development Intern at OHSU Technology Transfer and Business Development. In 2014, they then became a Research Fellow at the Knight Cardiovascular Institute, Oregon Health and Science University, where they worked until 2020. During this time, they gained scientific research experience. In 2020, they transitioned to Partek Inc., where they worked as a Field Application Scientist in the field of bioinformatics software until 2021. Following this, they joined Sema4 as a Project Manager in Bioinformatics R&D until 2022. Currently, they are working at Metrum Research Group as a Scientific Project Manager.

Uchenna Emechebe has an extensive education history. Uchenna completed their Bachelor's degree in Applied Microbiology at Nnamdi Azikiwe University from 1999 to 2001. Uchenna then pursued their Ph.D. in Neurobiology and Anatomy at the University of Utah School of Medicine, where they studied from 2006 to 2013.

After obtaining their Ph.D., Uchenna Emechebe went on to continue their education at Oregon Health & Science University. From 2014 to 2020, they worked as a postdoctoral fellow, focusing on Vascular Biology.

In addition to their formal education, Uchenna Emechebe has acquired several certifications. Uchenna completed various Coursera courses, such as "Introduction to Genomic Technologies," "Introduction to Big Data," "Exploratory Data Analysis," "Getting and Cleaning Data," "Machine Learning Foundations: A Case Study Approach," "R Programming," and "The Data Scientist's Toolbox." These courses were completed between 2016 and 2017.

Overall, Uchenna Emechebe's education and certifications have provided their with a strong foundation in microbiology, neurobiology, anatomy, vascular biology, and data analysis.

Links


Timeline

  • Scientific Project Manager - Model Informed Drug Development

    November, 2022 - present